BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Franco P, Dauvilliers Y, Inocente CO, Guyon A, Villanueva C, Raverot V, Plancoulaine S, Lin JS. Impaired histaminergic neurotransmission in children with narcolepsy type 1. CNS Neurosci Ther 2019;25:386-95. [PMID: 30225986 DOI: 10.1111/cns.13057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Lecendreux M, Plazzi G, Franco P, Jacqz-aigrain E, Robert P, Duvauchelle T, Schwartz J. Pharmacokinetics of pitolisant in children and adolescents with narcolepsy. Sleep Medicine 2020;66:220-6. [DOI: 10.1016/j.sleep.2019.10.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
2 Melzi S, Morel AL, Scoté-Blachon C, Liblau R, Dauvilliers Y, Peyron C. Histamine in murine narcolepsy: What do genetic and immune models tell us? Brain Pathol 2021;:e13027. [PMID: 34672414 DOI: 10.1111/bpa.13027] [Reference Citation Analysis]
3 Yoshikawa T, Nakamura T, Yanai K. Histaminergic neurons in the tuberomammillary nucleus as a control centre for wakefulness. Br J Pharmacol 2021;178:750-69. [PMID: 32744724 DOI: 10.1111/bph.15220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Franco P, Dauvilliers Y, Inocente CO, Guyon A, Villanueva C, Raverot V, Plancoulaine S, Lin JS. Impaired histaminergic neurotransmission in children with narcolepsy type 1. CNS Neurosci Ther 2019;25:386-95. [PMID: 30225986 DOI: 10.1111/cns.13057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
5 Sharma A, Muresanu DF, Patnaik R, Menon PK, Tian ZR, Sahib S, Castellani RJ, Nozari A, Lafuente JV, Buzoianu AD, Skaper SD, Bryukhovetskiy I, Manzhulo I, Wiklund L, Sharma HS. Histamine H3 and H4 receptors modulate Parkinson's disease induced brain pathology. Neuroprotective effects of nanowired BF-2649 and clobenpropit with anti-histamine-antibody therapy. Prog Brain Res 2021;266:1-73. [PMID: 34689857 DOI: 10.1016/bs.pbr.2021.06.003] [Reference Citation Analysis]
6 Berteotti C, Lo Martire V, Alvente S, Bastianini S, Bombardi C, Matteoli G, Ohtsu H, Lin JS, Silvani A, Zoccoli G. Orexin/Hypocretin and Histamine Cross-Talk on Hypothalamic Neuron Counts in Mice. Front Neurosci 2021;15:660518. [PMID: 34093114 DOI: 10.3389/fnins.2021.660518] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Zhang M, Inocente CO, Villanueva C, Lecendreux M, Dauvilliers Y, Lin JS, Arnulf I, Gustin MP, Thieux M, Franco P. Narcolepsy with cataplexy: Does age at diagnosis change the clinical picture? CNS Neurosci Ther 2020. [PMID: 32761857 DOI: 10.1111/cns.13438] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Li S, Yang J. Pitolisant for treating patients with narcolepsy. Expert Review of Clinical Pharmacology 2020;13:79-84. [DOI: 10.1080/17512433.2020.1714435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Cheng L, Liu J, Chen Z. The Histaminergic System in Neuropsychiatric Disorders. Biomolecules 2021;11:1345. [PMID: 34572558 DOI: 10.3390/biom11091345] [Reference Citation Analysis]
10 Shan L, Fronczek R, Lammers GJ, Swaab DF. The tuberomamillary nucleus in neuropsychiatric disorders. Handb Clin Neurol 2021;180:389-400. [PMID: 34225943 DOI: 10.1016/B978-0-12-820107-7.00024-0] [Reference Citation Analysis]